Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Soleno Therapeutics Inc SLNO

Healthcare Biotechnology
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, Diazoxide Choline Extended-Release tablets (DCCR), extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), recently completed its Phase 3... see more

Recent & Breaking News (NDAQ:SLNO)

Soleno Therapeutics Added to Russell 3000® Index

GlobeNewswire June 29, 2020

Soleno Therapeutics Announces Closing of $57.5 Million Public Offering of Common Stock, Including the Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire June 26, 2020

Soleno Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock

GlobeNewswire June 24, 2020

Soleno Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire June 23, 2020

Soleno Therapeutics Announces Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome

GlobeNewswire June 8, 2020

Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2020 Financial Results

GlobeNewswire May 12, 2020

Soleno Therapeutics Announces Publication Evaluating Potential Role of Activating ATP-Sensitive Potassium Channel in Treatment of Hyperphagic Obesity

GlobeNewswire April 23, 2020

Soleno Therapeutics to Present at the 30th Annual Oppenheimer Healthcare Conference

GlobeNewswire March 11, 2020

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2019 Financial Results

GlobeNewswire March 4, 2020

Soleno Therapeutics Completes Target Enrollment in Ongoing DESTINY PWS Phase III Trial of DCCR in Prader Willi Syndrome

GlobeNewswire January 6, 2020

Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2019 Financial Results

GlobeNewswire November 13, 2019

Soleno Therapeutics Announces Closing of $15.4 Million Public Offering of Common Stock

GlobeNewswire October 25, 2019

Soleno Therapeutics Announces Pricing of $13.4 Million Public Offering of Common Stock

GlobeNewswire October 23, 2019

Soleno Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire October 22, 2019

Soleno Therapeutics Announces Positive Outcome from Second Planned Data Safety Monitoring Board Review of Phase III DESTINY PWS Clinical Trial of DCCR in Prader-Willi Syndrome

GlobeNewswire October 2, 2019

Soleno Therapeutics Announces Publication of Results from Previously Completed Phase II Trial of DCCR for Treatment of Prader-Willi Syndrome

GlobeNewswire September 24, 2019

Soleno Therapeutics to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies

GlobeNewswire September 19, 2019

Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2019 Financial Results

GlobeNewswire August 7, 2019

Soleno Therapeutics Provides Update on Ongoing DESTINY PWS Phase III Trial of DCCR in Prader-Willi Syndrome

GlobeNewswire July 25, 2019

Soleno Therapeutics Announces Appointment of Veteran Industry Executive Birgitte Volck, M.D., Ph.D., to Board of Directors

GlobeNewswire June 12, 2019